89bio to Present at Upcoming Investor Conference

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will present at the H.C. Wainwright 4th Annual NASH Investor Conference on Monday, October 5, 2020 at 11:30 AM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.89bio.com/events-and-presentations. The replay of the webcast will be available on the company’s website.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:Ryan MartinsChief Financial Officer[email protected]

Media Contact:Lori RosenLDR Communications917-553-6808[email protected]

You May Also Be Interested In

• Instruqt Becomes the First and Only Platform to Pair AI-Assisted Content Creation with Native Vertex AI, Amazon Bedrock, and GPU Environments
• MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
• Nyrstar NV provides an update with respect to the extraordinary general shareholders’ meeting to be held on 30 June 2026